Barclays PLC Ocugen, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Ocugen, Inc. stock. As of the latest transaction made, Barclays PLC holds 581,087 shares of OCGN stock, worth $447,436. This represents 0.0% of its overall portfolio holdings.

Number of Shares

581,087

Previous 581,087 -0.0%

Holding current value

$447,436

Previous $577,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$0.98 - $1.95 $290,720 - $578,475	296,654 Added 104.3%	581,087 $577,000
Q2 2024 Aug 14, 2024	BUY	$1.18 - $1.98 $335,630 - $563,177	284,433 New	284,433 $440,000
Q1 2023 May 04, 2023	SELL	$0.82 - $1.33 $965,210 - $1.57 Million	-1,177,086 Reduced 91.47%	109,802 $93,000
Q4 2022 Feb 13, 2023	BUY	$1.11 - $1.87 $93,957 - $158,288	84,646 Added 7.04%	1,286,888 $1.67 Million
Q3 2022 Nov 03, 2022	BUY	$1.75 - $3.1 $2.08 Million - $3.68 Million	1,188,660 Added 8751.73%	1,202,242 $2.14 Million
Q2 2022 Aug 12, 2022	BUY	$1.83 - $3.45 $24,855 - $46,857	13,582 New	13,582 $30,000

Others Institutions Holding OCGN

# of Institutions

124

Shares Held

78.3M

Call Options Held

535K

Put Options Held

523K

View Full List

About Ocugen, Inc.

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

More about OCGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account